Arcellx Details Executive Compensation & Change-in-Control Payouts Amidst Gilead Acquisition
ACLX has more than doubled off its 52-week low of $47.86.
Summary
Arcellx filed an amended 10-K to disclose detailed executive compensation, including 150% bonus payouts for 2025, full equity acceleration upon the Gilead acquisition, and potential $25M tax gross-up payments for executives.
Key Events · M&A and Partnerships · ACLX
-
Executive Compensation Details Disclosed
The 10-K/A includes comprehensive executive compensation for 2025, with CEO Rami Elghandour receiving $18.18 million, CFO Michelle Gilson $7.04 million, and CMO Christopher Heery $4.77 million.
-
150% Achievement of 2025 Annual Bonus Plan
Named executive officers received 150% of their target annual bonuses for 2025, reflecting the company's strong performance against budgetary, manufacturing, clinical, commercial, and research goals.
-
Full Equity Acceleration Upon Acquisition
All outstanding equity awards held by named executive officers, other employees, and directors will fully vest immediately prior to the consummation of the acquisition by Gilead Sciences.
-
Potential $25M Tax Gross-Up Payments
Arcellx may pay up to an aggregate of $25 million, including gross-up payments, to employees and executive officers to cover Section 4999 excise taxes resulting from parachute payments related to the merger.
Analysis · ACLX · Life Sciences
This 10-K/A filing provides crucial details regarding executive compensation and the financial implications of the pending acquisition by Gilead Sciences, information previously omitted from the original 10-K. The disclosure highlights significant payouts for named executive officers, including 150% achievement of 2025 annual bonuses, reflecting strong operational performance leading up to the acquisition. Critically, all outstanding equity awards for executives and directors will fully accelerate upon the closing of the merger. Furthermore, the company may pay up to $25 million in gross-up payments to employees, including executives, to cover Section 4999 excise taxes related to parachute payments. These details are highly material for investors to understand the full financial impact of the acquisition on key personnel, especially as the stock trades near its 52-week high, aligning closely with the acquisition price.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACLX was trading at $115.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7B. The 52-week trading range was $47.86 to $115.13. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.